We also provide data to support the efficacy of targeting the LPL pathway in treating CAD and T2D, either as stand-alone or in combination with licensed lipid-lowering drug targets, with evidence of additive, but not multiplicative effects. This evidence concerns the gene LPL and coronary artery disorder.